Target Name: WDFY1
NCBI ID: G57590
Review Report on WDFY1 Target / Biomarker Content of Review Report on WDFY1 Target / Biomarker
WDFY1
Other Name(s): ZFYVE17 | KIAA1435 | WDF1 | WD repeat and FYVE domain containing 1 | OTTHUMP00000203772 | Phosphoinositide-binding protein 1 | FYVE domain-containing protein localized to endosomes 1 | WDFY1_HUMAN | WD40 and FYVE domain containing 1 | FENS-1 | zinc finger FYVE domain-containing protein 17 | phosphoinositide-binding protein SR1 | FENS1 | WD repeat and FYVE domain-containing protein 1 | Zinc finger FYVE domain-containing protein 17 | Phosphoinositide-binding protein SR1 | WD40- and FYVE domain-containing protein 1

WDFY1: A Protein Implicated in A Variety of Diseases

WDFY1 (ZFYVE17) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of cell growth and differentiation, and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the WDFY1 protein's most significant functions is its role in cell signaling. It is a protein that is involved in a variety of signaling pathways, including the TGF-β pathway, the Wnt pathway, and the Hedgehog pathway. These pathways are involved in the regulation of cell growth, differentiation, and survival, and are critical for the development and maintenance of tissues and organs.

Another important function of WDFY1 is its role in the regulation of inflammation. It is a protein that is involved in the production of pro-inflammatory cytokines, which are important for the recruitment of immune cells to sites of injury or infection. This function is important for the regulation of both acute and chronic inflammation, and for the regulation of inflammation-related diseases such as autoimmune disorders and inflammatory bowel disease.

In addition to its role in cell signaling and inflammation, WDFY1 is also involved in the regulation of cell survival. It is a protein that is involved in the regulation of cell cycle progression, which is the process by which cells grow and divide. This function is important for the regulation of both normal cell growth and the treatment of cancer.

The identification of WDFY1 as a potential drug target or biomarker has significant implications for the development of new treatments for a variety of diseases. By targeting WDFY1 with small molecules or other therapeutic agents, researchers may be able to inhibit its functions as a drug, which could lead to the treatment of a wide range of diseases.

For example, in cancer, WDFY1 has been shown to be involved in the regulation of cell growth and survival, which makes it an attractive target for cancer therapies. By inhibiting WDFY1 function, researchers may be able to inhibit the growth and spread of cancer cells , leading to a reduction in the risk of cancer recurrence.

In neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, WDFY1 has been implicated in the regulation of cell survival and the development of neurodegeneration. By targeting WDFY1 with therapeutic agents, researchers may be able to treat these diseases and slow the progression of neurodegeneration.

In autoimmune disorders, such as rheumatoid arthritis and lupus, WDFY1 has been shown to be involved in the regulation of immune responses. By targeting WDFY1 with small molecules or other therapeutic agents, researchers may be able to treat these disorders and reduce the severity of their symptoms.

Overall, the identification of WDFY1 as a potential drug target or biomarker has significant implications for the development of new treatments for a wide range of diseases. By targeting WDFY1 with small molecules or other therapeutic agents, researchers may be able to inhibit its functions and treat a variety of conditions.

Protein Name: WD Repeat And FYVE Domain Containing 1

Functions: Positively regulates TLR3- and TLR4-mediated signaling pathways by bridging the interaction between TLR3 or TLR4 and TICAM1. Promotes TLR3/4 ligand-induced activation of transcription factors IRF3 and NF-kappa-B, as well as the production of IFN-beta and inflammatory cytokines (PubMed:25736436)

The "WDFY1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WDFY1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WDFY2 | WDFY3 | WDFY3-AS2 | WDFY4 | WDHD1 | WDPCP | WDR1 | WDR11 | WDR11-DT | WDR12 | WDR13 | WDR17 | WDR18 | WDR19 | WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82 | WDR82P1 | WDR83 | WDR83OS | WDR86 | WDR86-AS1 | WDR87 | WDR88 | WDR89 | WDR90 | WDR91 | WDR93 | WDR97 | WDSUB1 | WDTC1 | WEE1 | WEE2 | WEE2-AS1 | WFDC1 | WFDC10A | WFDC10B | WFDC11 | WFDC12 | WFDC13 | WFDC2 | WFDC21P | WFDC3 | WFDC5 | WFDC6 | WFDC8 | WFDC9 | WFIKKN1 | WFIKKN2 | WFS1 | WHAMM | WHAMMP1 | WHAMMP2 | WHAMMP3 | WHRN | WIF1 | WIPF1 | WIPF2 | WIPF3 | WIPI1 | WIPI2